title: Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study.
abstract: Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β(2) microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level. The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β(2) microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.
authors.affiliation: Ph.D. Scholar, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Gajendra
authors.initials: G
authors.lastname: Kumar
authors.forename: Amita
authors.initials: A
authors.lastname: Srivastava
authors.forename: Surinder Kumar
authors.initials: SK
authors.lastname: Sharma
authors.forename: Yogendra Kumar
authors.initials: YK
authors.lastname: Gupta
keywords: Arjuna; Arogyavardhini Vati; dyslipidemia; efficacy; safety
references.citation: J Lipid Res. 1989 Jan;30(1):39-49
references.pmid: 2493057
references.citation: Platelets. 2009 May;20(3):183-90
references.pmid: 19437336
references.citation: Nat Med. 2002 Nov;8(11):1218-26
references.pmid: 12411948
references.citation: Diabetes Res Clin Pract. 2003 Jun;60(3):199-204
references.pmid: 12757982
references.citation: Circulation. 1999 Jul 6;100(1):96-102
references.pmid: 10393687
references.citation: J Clin Invest. 2003 Jun;111(12):1805-12
references.pmid: 12813013
references.citation: J Adv Pharm Technol Res. 2010 Apr;1(2):229-35
references.pmid: 22247850
references.citation: JAMA. 1994 Mar 2;271(9):672-7
references.pmid: 8309029
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: Circulation. 1998 May 26;97(20):2007-11
references.pmid: 9610529
references.citation: Am J Cardiol. 2005 Nov 1;96(9):1278-9
references.pmid: 16253597
references.citation: Am Heart Hosp J. 2007 Winter;5(1):32-7
references.pmid: 17268226
references.citation: Indian J Exp Biol. 2011 Apr;49(4):282-8
references.pmid: 21614892
references.citation: J Nat Prod. 2001 Aug;64(8):1010-4
references.pmid: 11520216
references.citation: Fitoterapia. 2006 Dec;77(7-8):579-84
references.pmid: 17056204
references.citation: Indian J Exp Biol. 2009 Jul;47(7):577-83
references.pmid: 19761042
references.citation: Hepatology. 2005 Apr;41(4):690-5
references.pmid: 15789367
references.citation: Drug Chem Toxicol. 2007;30(3):241-52
references.pmid: 17613009
references.citation: Int J Food Sci Nutr. 2011 Sep;62(6):609-16
references.pmid: 21495900
references.citation: Lancet. 1999 Apr 10;353(9160):1274
references.pmid: 10217112
references.citation: Am J Cardiol. 1998 Feb 26;81(4A):60B-65B
references.pmid: 9526816
references.citation: Yakugaku Zasshi. 2007 Feb;127(2):385-8
references.pmid: 17268159
references.citation: J Ethnopharmacol. 2012 Mar 6;140(1):151-60
references.pmid: 22265750
references.citation: J Assoc Physicians India. 2001 Feb;49:231-5
references.pmid: 11225136
references.citation: Clin Nephrol. 2001 Jan;55(1):39-44
references.pmid: 11200866
references.citation: Circulation. 1999 Sep 14;100(11):1148-50
references.pmid: 10484532
references.citation: Planta Med. 1991 Feb;57(1):29-33
references.pmid: 2062954
references.citation: J Ethnopharmacol. 2002 Jan;79(1):81-7
references.pmid: 11744299
references.citation: J Hepatol. 2002 Apr;36(4):454-8
references.pmid: 11943414
references.citation: Drug Saf. 2000 Sep;23(3):197-213
references.pmid: 11005703
references.citation: Complement Ther Med. 2009 Jan;17(1):16-22
references.pmid: 19114224